Working… Menu

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03637543
Recruitment Status : Recruiting
First Posted : August 20, 2018
Last Update Posted : September 22, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
David J. Einstein, MD, Beth Israel Deaconess Medical Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 31, 2025